Nothing Special   »   [go: up one dir, main page]

AR078471A1 - COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS - Google Patents

COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS

Info

Publication number
AR078471A1
AR078471A1 ARP100103531A ARP100103531A AR078471A1 AR 078471 A1 AR078471 A1 AR 078471A1 AR P100103531 A ARP100103531 A AR P100103531A AR P100103531 A ARP100103531 A AR P100103531A AR 078471 A1 AR078471 A1 AR 078471A1
Authority
AR
Argentina
Prior art keywords
conjugates
maitansinoid
antibody
compounds
preparation procedure
Prior art date
Application number
ARP100103531A
Other languages
English (en)
Inventor
Herve Bouchard
Alain Commercon
Claudia Fromond
Fabienne Parker
Ingrid Sassoon
Vincent Mikol
Daniel Tavares
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR078471A1 publication Critical patent/AR078471A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compuesto de la formula (1), en donde: ALK es un grupo alquileno C1-6; X1 y X2 son cada uno independientemente uno de los grupos siguientes -CH=CH-, -CO-, -CONR-, -NRCO-, -COO-, -OCO-, -OCONR-, -NRCOO-, -NRCONR'-, -NR-, -S(O)n (n = 0, 1 o 2) o -O-; R y R' son independientemente H o un grupo alquilo C1-6; i es un numero entero de 1 a 40, preferiblemente de 1 a 20, y más preferiblemente de 1 a 10; j es un numero entero que corresponde a 1 cuando X2 es -CH=CH- y 2 cuando X2 no es -CH=CH-; Zb es un enlace sencillo, -O- o -NH- y Rb es H o un grupo alquilo C1-6, cicloalquilo C3-7, arilo, heteroarilo o heterocicloalquilo C3-7; o Zb es un enlace sencillo y Rb es Hal. Su uso como anticancerígeno. Reivindicacion 17: Conjugado segun la reivindicacion 16 que tiene un DAR promedio, medido con un espectrometro UV por encima de 4, más particularmente entre 4 y 10, incluso más particularmente entre 4 y 7, estando determinado el DAR mediante la ecuacion siguiente: DAR = cD / cA con: cD = [(eA280 x A252) - (eA252 x A280)] / [(eD252 x eA280) - (eA252 x eD280)]; cA = [A280 - (cD x eD280)] / eA280; eD252 = 26.159 M-1cm-1; eD280 = 5.180 M-1cm-1; eA280 = 224.000 M-1cm-1; eA252 = 82.880 M-1cm-1; siendo A252 y A280 las absorbancias del conjugado medidas en el espectrometro UV a 252 y 280 hm respectivamente.
ARP100103531A 2009-10-02 2010-09-29 COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS AR078471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09305939 2009-10-02

Publications (1)

Publication Number Publication Date
AR078471A1 true AR078471A1 (es) 2011-11-09

Family

ID=41698152

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103531A AR078471A1 (es) 2009-10-02 2010-09-29 COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS

Country Status (24)

Country Link
US (1) US20120276124A1 (es)
EP (1) EP2483279A1 (es)
JP (1) JP2013506653A (es)
KR (1) KR20120091166A (es)
CN (1) CN102741260A (es)
AR (1) AR078471A1 (es)
AU (1) AU2010302247A1 (es)
BR (1) BR112012007305A2 (es)
CA (1) CA2774916A1 (es)
CL (1) CL2012000820A1 (es)
CR (1) CR20120147A (es)
EA (1) EA201270473A1 (es)
EC (1) ECSP12011756A (es)
IL (1) IL218740A0 (es)
MA (1) MA33702B1 (es)
MX (1) MX2012003998A (es)
NI (1) NI201200051A (es)
NZ (1) NZ599045A (es)
PE (1) PE20121534A1 (es)
TN (1) TN2012000115A1 (es)
TW (1) TW201117814A (es)
UY (1) UY32913A (es)
WO (1) WO2011039721A1 (es)
ZA (1) ZA201202328B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
TW201116297A (en) * 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
KR102351886B1 (ko) 2011-03-29 2022-01-17 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
EP2904089A4 (en) 2012-10-04 2016-05-25 Immunogen Inc USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
NO2789793T3 (es) * 2012-10-24 2018-01-27
BR112015008376A2 (pt) * 2012-10-24 2017-09-26 Polytherics Ltd conjugados fármaco-proteína
CN103333179B (zh) * 2012-12-21 2017-06-16 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
WO2014145090A1 (en) 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
US20160143914A1 (en) * 2013-06-13 2016-05-26 Emory University Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
CN103483357B (zh) * 2013-10-12 2015-11-18 齐鲁制药有限公司 一种抗体-美登素偶联物的中间体新晶型及其制备方法
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
US9562059B2 (en) * 2013-12-02 2017-02-07 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
EP3220959A1 (en) 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
JP6802840B2 (ja) 2015-06-09 2020-12-23 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド 抗体薬物複合体、中間体、その製造方法、薬学的組成物及び応用
JP6638970B2 (ja) * 2015-06-30 2020-02-05 株式会社 東北テクノアーチ ヘテロ型単分散ポリエチレングリコール、ヘテロ型単分散ポリエチレングリコール製造用中間体の製造方法
US12102689B2 (en) 2015-11-09 2024-10-01 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
US9950076B2 (en) 2016-01-25 2018-04-24 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
US10195283B2 (en) * 2016-03-18 2019-02-05 R.P. Scherer Technologies, Llc Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate
CN107652219B (zh) 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
EP1578446B1 (en) 2002-11-07 2015-04-08 ImmunoGen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
WO2004100885A2 (en) * 2003-05-09 2004-11-25 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
CN101186613B (zh) 2003-05-20 2014-09-17 伊缪诺金公司 含有新的美登素类的改进的细胞毒剂
WO2005009369A2 (en) 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
CA3005835C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2006280146B2 (en) 2005-08-09 2012-06-28 Immunogen, Inc. Method of acylating maytansinol with chiral amino acids
CA2893252C (en) * 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EA020324B1 (ru) * 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
BRPI0911442A2 (pt) * 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
TW201116297A (en) * 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor

Also Published As

Publication number Publication date
EA201270473A1 (ru) 2013-02-28
KR20120091166A (ko) 2012-08-17
WO2011039721A1 (en) 2011-04-07
CN102741260A (zh) 2012-10-17
IL218740A0 (en) 2012-06-28
JP2013506653A (ja) 2013-02-28
BR112012007305A2 (pt) 2016-12-06
AU2010302247A1 (en) 2012-04-26
CL2012000820A1 (es) 2012-08-31
MA33702B1 (fr) 2012-10-01
EP2483279A1 (en) 2012-08-08
ECSP12011756A (es) 2012-07-31
TW201117814A (en) 2011-06-01
CA2774916A1 (en) 2011-04-07
CR20120147A (es) 2012-06-01
UY32913A (es) 2011-04-29
NI201200051A (es) 2012-08-09
US20120276124A1 (en) 2012-11-01
MX2012003998A (es) 2012-04-20
PE20121534A1 (es) 2012-12-03
NZ599045A (en) 2013-09-27
ZA201202328B (en) 2014-06-25
TN2012000115A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
AR078471A1 (es) COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
UY39128A (es) Composiciones y métodos para modular la senda de señalización de wnt
AR057324A1 (es) Tigeciclina y metodos para preparar 9-aminominociclina
ECSP13012410A (es) Composiciones y métodos para modular la vía de señalización de wnt
PE20141378A1 (es) Moduladores de receptores de glucocorticoides de pirimidina ciclohexilo
CR9543A (es) Tigeciclina y metodos para preparar 9-nitrominociclina
ECSP078059A (es) Tigeciclina y métodos de preparación
EA201300335A1 (ru) Композиция, содержащая пирипиропеновый инсектицид и адъювант
DOP2008000089A (es) 18-metil-19-nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen
CO6670522A2 (es) Conjugados de anticuerpos multifuncionales de anticuerpos anti-igf1r, derivados de los mismos y composiciones que los contienen
PE20060932A1 (es) Derivados de sulfonamidas como moduladores de receptores de glucocorticoides (gr)
CR9542A (es) Metodos para purificar tigeciclina
CU24317B1 (es) Conjugado de naloxol-peg cristalino
ECSP088360A (es) Métodos para preparar derivados de ácido glutámico
CR11635A (es) Procedimiento de preparacion de combretastatina
DOP2012000084A (es) Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo
BR112012029944A2 (pt) processo para preparação de derivados de aminotetralinas substituídas com nitrogênio
MX2012005596A (es) Derivados de difenil azepano como inhibidores de reabsorcion de monoaminas.
ECSP099396A (es) Nuevos derivados azabicíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR077768A1 (es) Alcoxilatos de cocoalquilpoliamina como agentes para composiciones herbicidas de alto poder
MA33882B1 (fr) Nouveaux derives azabicyclo [3.1.0]hex-2-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
CO6602120A2 (es) Pirrolidina-25-carboxamidas sustituidas
CR20130040A (es) Composiciones y métodos para modular la vía de señalización de wnt
CO6280059A1 (es) Nuevos derivados de azabiciclos (3.2.0) hept-3-ilo su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal